Currently myeloma is treated if CRAB criteria develop. To prevent CRAB criteria, especially bone lesions, and to increase the ability to potentially cure myeloma, there are now many efforts to securely diagnose early active myeloma. The goal is to treat as early as possible when treatment is definitely necessary and to improve outcomes.
A new study from the Mayo Clinic myeloma team, with Vincent Rajkumar as the senior author, shows that circulating plasma cell levels can be a helpful marker of early active disease. It is likely that other tests and markers will be added to the portfolio of methods used to introduce new therapies at the best early time point.